The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

The present invention relates to preparation and biological evaluation of 3-acetoxy-17-acetamido-16-formyl-androst-517-diene (4) and 3-acetoxy2'-chloro-5-androsteno[1716-b]pyridine (5) as gastric proton pump inhibitor and their comparison to that of omeprazole a clinically employed anti-gastric ulcer drug. Compound (4) exhibited dose dependent inhibition of histamine-stimulated acid secretion in gastric parietal cell with an IC50 value comparable to cimetidine. No mortality or behavioral abnorma...